Molecular determinants of peptide and non-peptide binding to the AT1 receptor

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue SUPPL. 3, 1996, Pages

  Karnik, Sadashiva S ^a   Husain, Ahsan ^a   Graham, Robert M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

Angiotensin II; Binding affinity; Ligand residues; Losartan; Structure function

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; LOSARTAN POTASSIUM; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; RECEPTOR PROTEIN; ANGIOTENSIN II; BIPHENYL DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; VASOCONSTRICTOR AGENT;

CONFERENCE PAPER; DRUG RECEPTOR BINDING; HUMAN; MUTATION; PHENOTYPE; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; AMINO ACID SEQUENCE; ANIMAL; BINDING COMPETITION; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOLECULAR GENETICS; POINT MUTATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SPECIES DIFFERENCE;

AMINO ACID SEQUENCE; ANGIOTENSIN II; ANIMALS; BINDING SITES; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECEPTOR, ANGIOTENSIN, TYPE 1; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; DOWN-REGULATION; GTP-BINDING PROTEINS; IMIDAZOLES; LOSARTAN; PHENOTYPE; POINT MUTATION; RECEPTORS, ANGIOTENSIN; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SPECIES SPECIFICITY; TETRAZOLES; VASOCONSTRICTOR AGENTS;

EID: 0029731151     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Bumpus FM, Khosla MC. Angiotensin analogs as determinants of the physiological role of angiotensin and its metabolite. In: Genest J, Koiw E, Kuchel O (eds). Hypertension: Physiology and Treatment. McGraw-Hill, New York. 1977; 183-201.
2. Marshall GR, Bosshard HE, Vine WH, Glickson JD, Needleman P. Pharmacology of antagonists of angiotensin I and II. In: Wesson LG, Fanelli GM Jr (eds). Recent Advances in Renal Phsyiology and Pharmacology. University Park Press, Baltimore. 1974: 215-56.
3. Timmermans PBMWM, Wong PG, Chin AT et al. Angiotensin II receptors and angtiotensin II receptor antagonists. Pharmacol. Rev. 1993; 45: 205-51.
4. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-6.
5. 1). J. Biol. Chem. 1995; 270: 14 024-30.
6. Ji H, Zheng W, Zhang Y, Catt KJ, Sandberg K. Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor. Proc. Natl Acad. Sci. USA 1995; 92: 9240-4.
7. 1 receptor is a single copy gene: Characterisation in a stable cell line. Mol. Cel. Biochem. 1994; 131: 75-86.
8. 2 receptor: Searching for signal-transduction pathways and physiological function. Trends. Pharmacol. Sci. 1995; 16: 223-5.
9. (1) receptor: Gain-of-function study using gene transfer. Proc. Natl Acad. Sci. USA 1995; 92: 10 663-7.
10. Iismaa T, Biden T, Shine J. G-protein-coupled receptors. RG Landes Company, Austin, TX 1994.
11. Noda K, Saad Y, Kinoshita A et al. Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J. Biol. Chem. 1995; 270: 2284-9.
12. Yamano Y, Ohyama K, Chaki S, Guo D-F, Inagami T. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site-directed mutagenesis. Biochem. Biophys. Res. Commun. 1992, 187: 1426-31.
13. Hsieh K-H, Marshall GR. Role of the C-terminal carboxylate in angiotensin II activity: Alcohol, ketone, and ester analogues of angiotensin II. J. Med. Chem. 1986; 29: 1968-71.
14. Furukawa Y, Kishimoto S, Nishikawa K (inventors). Takeda Chemical Industries Ltd (assignee). Novel imidazole derivatives of the formula: 'STR1' wherein R.sup.1 is lower alkyl or, phenyl-C. sub. 1-2 alkyl which may be substituted with halogen or nitro. US Patent 4 340 598. 20 July 1982.
15. Furukawa Y, Kishimoto S, Nishikawa K (inventors). Takeda Chemical Industries Ltd (assignee). Hypertensive imidazole-S-acetic acid derivatives. US Patent 4 355 040. 19 October 1982.
16. Prendergast K, Adams K, Greenlee WJ, Nachbar RB, Patchett AA, Underwood DJ. Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor. J. Comp. Aided Mol. Des. 1994; 8: 491-512.
17. Duncia J-V, Chiu AT, Carini DJ et al. The discovery of potent nonpeptide angiotensin II receptor antagonists: A new class of potent antihypertensives. J. Med. Chem. 1990; 33: 1312-29.
18. Carini DJ, Duncia JV, Aldrich PE et al. Nonpeptide angiotensin II receptor antagonists: The discovery of a series of N-(biphenylylmethyl) imidazoles as potent, orally active antihypertensives. J. Med. Chem. 1991; 34: 2525-47.
19. 1 receptor is essential for full agonism. J. Biol. Chem. 1995; 270: 12 846-50.
20. 1 receptor in agonist activation. J. Biol. Chem. 1995; 270: 28 511-14.
21. Hunyady L, Bor M, Balla T, Catt K. Critical role of a conserved intramembrane tyrosine residue in angiotensin II receptor activation. J. Biol. Chem. 1995; 270: 9702-5.
22. Schambye HT, Hjorth SA, Weinstock J, Schwartz TW. Interaction between the nonpeptide angiotensin antagonist SKF-108 566 and histidine 256 (HisVI: 16) of the angiotensin type 1 receptor. Mol. Pharmacol. 1994; 47: 425-31.
23. 1 angiotensin receptor. J. Biol. Chem. 1994; 269: 16 533-6.
24. Kurtenbach E, Curtis CAM, Pedder EK, Aitken A, Harris ACM, Hulme EC. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. J. Biol. Chem. 1990; 265: 13 702-8.
25. 1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. J. Biol. Chem. 1992; 85: 11 439-48.
26. Karnik SS, Sakmar TP, Chen HB, Khorana HG. Cysteine residues 110 and 187 are required for the formation of correct tertiary structure in bovine rhodopsin. Proc. Natl Acad. Sci. USA 1988; 85: 8459-63.
27. Karnik SS, Khorana HG. Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 187. J. Biol. Chem. 1990; 256: 17 520-4.
28. Noda K, Saad Y, Graham RM, Karnik SS. The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. J. Biol. Chem. 1994; 269: 6743-52.
29. A. Reg. Peptides. 1995; 57: 141-7.
30. Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW. Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc. Natl Acad. Sci. USA 1994; 91: 7046-50.
31. 1 receptor. J. Biol. Chem. 1994; 269: 30 953-9.
32. 74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-protein coupling. Proc. Natl Acad. Sci. USA 1993; 90: 5133-7.
33. 1A angiotensin II receptor is essential for its coupling to phospholipase C. J. Biol. Chem. 1994; 269: 20 815-18.
34. Riek RP, Handschumacher MK, Sung S et al. Evolutionary conservation of both the hydrophilic and hydrophobic nature of transmembrane residues. J. Theoret. Biol. 1995; 172: 245-58.
35. 1-adrenergic receptor subtypes identify critical residues that modulate active-state isomerisation. J. Biol. Chem. 1996; 271: 7956-64.